Kala Pharmaceuticals to change name to KALA BIO

Kala Pharmaceuticals announced that it will change its name to KALA BIO effective August 2, 2023, to better reflect the company’s focus on advancing biologics for the treatment of ophthalmic conditions. KALA BIO is progressing an innovative pipeline built on its proprietary mesenchymal stem cell secretome platform, which is designed to provide a cell-free, regenerative approach to disease management, with the potential to treat multiple diseases of the front and back of the eye. “KALA BIO is committed to developing innovative therapies for rare and severe diseases of the eye,” said Mark Iwicki, Chair and Chief Executive Officer of KALA BIO. “Our primary focus is the utilization of our MSC-S platform to develop novel therapies for ophthalmic diseases. Now that we are enrolling patients in the CHASE Phase 2b clinical trial of KPI-012 for the treatment of persistent corneal epithelial defect and evaluating the potential development of KPI-012 and KPI-014 for additional eye diseases, we believe it is the perfect time to launch KALA BIO and highlight our new mission of delivering a suite of novel biologics to improve the care and treatment of rare ocular diseases.”